China Rallies Behind Coronavirus Vaccines But Small Players May Have Best Shot
BravoVax CEO Sees Advantages For Nimble Firms
Ke Wu, CEO of Wuhan-based BravoVax, tells Scrip in an exclusive interview why front-runner vaccines for coronavirus that enter clinical studies may not necessarily be successful, and why small innovative Chinese firms may be best positioned to seize opportunities as the government rallies both internal and external support for the development effort.
You may also be interested in...
Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.
Leveraging on its Ebola vaccine success, Tianjin-based CanSino is testing its vaccine on humans in Wuhan and hopes to get China’s first COVID-19 vaccine on the market soon.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.